Bexmarilimab and azacitidine showed continued tolerability and a high overall response rate in relapsed/refractory higher-risk myelodysplastic syndromes in a phase 2 study.

Patients with diabetic macular edema treated with intravitreal aflibercept have a significantly higher risk of adverse renal events compared with those treated with ranibizumab.

The FDA has approved Isturisa (osilodrostat) for the treatment of endogenous hypercortisolemia in adults with Cushing syndrome for whom surgery is not an option or has not been curative.

Recent advances have marked a turning point for the treatment noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), with more therapies on the horizon to hopefully better address ...